Background: This study examined the interaction between natural history, current practice patterns in diagnosis, monitoring and treatment of oesophageal cancer, and associated health resource utilization and costs.
Conclusion:
Overall costs for managing oesophageal cancer were high and dominated by surgery costs in patients treated surgically and by chemotherapy costs in patients treated without surgery; radiotherapy, treatment location and cancer subtype were also important. Monitoring for Barrett's oesophagus and earlier stage detection were associated with lower management costs, but the potential net benefit from surveillance strategies needs further investigation.
+A: Introduction
The incidence of oesophageal adenocarcinoma in Western nations has grown four-to fivefold over the past 30 years 1,2 , with a parallel increase in the number of deaths from this cancer of [4] [5] [6] [7] per cent annually 1 . Less than 20 per cent of people currently diagnosed with oesophageal cancer can expect to survive beyond 5 years 1 , although there is much scope for improving survival
given that early detection of oesophageal adenocarcinoma is associated with a 5-year survival rate of 70-95 per cent 3 .
The mainstay of treatment for earlier stage cancer is oesophagectomy. Chemotherapy and radiotherapy are used before surgery in patients undergoing resection of more advanced disease, and are the principal treatment in patients unwilling or unfit for surgery, as well as in those with disseminated disease. The clinical course of the cancer can vary markedly, with a low proportion of at-risk patients currently proceeding straight to diagnosis and surgery 4 . A detailed understanding of resource utilization for the treatment of this disease remains elusive. Compared with many other cancer populations, healthcare resource use and costs in patients diagnosed with oesophageal cancer may potentially be high owing to a protracted disease process, frequent treatment-related complications, and the high number and frequency of monitoring and diagnostic investigations [4] [5] [6] .
Considering the relatively poor survival outlook for patients with advanced disease, there is a strong incentive to develop health technologies that will either detect cancer earlier or treat patients more effectively, while containing healthcare costs. Management options have expanded over the past decade, with new ablative therapies, enhanced imaging, endoscopic mucosal resection, and calls for standardized surveillance of Barrett's oesophagus [7] [8] [9] . However, these strategies are suitable only for early-stage disease, and most patients still present with advanced cancer.
Only one previous study has attempted to track healthcare resources and costs in treating oesophageal cancer at the patient level. That study was conducted a decade ago, before many of the current management and therapy alternatives were available, and it analysed a sample of only 29 patients from one centre 4 . It was not large enough to allow practice patterns to be explored.
Hence, studies assessing the cost-effectiveness of alternative oesophageal cancer treatments 10, 11 in jurisdictions of interest have relied on assumptions, rather than patient data, to inform treatment pathways and associated base-level probabilities, outcomes and their interaction with treatment effects 12, 13 . The absence of evidence to inform practice patterns, and the interaction of practice patterns with natural history, reduce the validity of the findings of all of these modelling studies 10, 11, 14 . In view of these gaps in the evidence, the present authors sought to identify treatment patterns and their interaction with natural history, to quantify the type and extent of resources used to treat actual patients with oesophageal cancer in Australia, and to analyse the attendant healthcare costs. To account for the right-censored data, mean costs by surgical versus non-surgical groups
+A: Methods

Patient
were assessed for variation in baseline clinical or patient factors using the three-part model of Basu and Manning 26 . First, an accelerated failure-time generalized gamma regression model provided the survival and hazard functions. Second, for patients whose costs were fully observed, a gamma generalized linear model with square-root link was undertaken. Third, for patients in whom censoring occurred, an extended estimating equation using a flexible Box-Cox link function and power variance function was performed (using STATA command 'PGLM') 27 .
Goodness-of-fit and model specification were assessed with normality tests, Pearson's correlation, Pregibon's link test, and visual assessment for systematic bias in the residuals across deciles of linear predictors and for v-fold cross-validation with the Copas test for overfitting 28 .
Data were analysed using STATA ® SE 11.0 (StataCorp, College Station, Texas, USA).
+A: Results
The mean age of participants was 64 years at diagnosis; 79.6 per cent were men, and most were partnered (77.4 per cent) ( Table S1, Table 2 ). Of participants with squamous cell carcinoma, 66.9 per cent received both radiation and chemotherapy, compared with 52 per cent of patients with adenocarcinoma of the oesophagus and 37.6 per cent of those with adenocarcinoma of the gastro-oesophageal junction.
The four most commonly used chemotherapy agents were 5-fluorouracil, cisplatin, epirubicin hydrochloride and carboplatin. These accounted for 93.6 per cent of all administrations; a total of 25 agents was used in the sample overall. In both surgical and non-surgical subgroups, mixed results were found for costs by rurality, with no significant differences found between participants living in inner or outer regional areas compared with metropolitan locations. As numbers were very small in the remote and very remote categories, cost figures were unstable, as indicated by the 95 per cent c.i. (Tables S3 and   S4 , supporting information).
+B: Multivariable analyses
In multivariable regression analyses, extended survival (in months) was significantly associated with having an oesophagectomy, as well as endoscopic surveillance of Barrett's oesophagus, whereas shorter survival was associated with more advanced tumour stage and tumour location at the gastro-oesophageal junction ( 30 studied the costs of nursing follow-up care over 12 months and concluded that nurse-led care achieved cost savings compared with standard follow-up, although the differences in this study were not statistically significant. The present data are likely to be more robust, for several reasons. First, a much larger patient cohort was incorporated and this enabled three cancer subtypes to be evaluated with sufficient power for multivariable regression analysis.
Second, a wide range of resources throughout the disease course was covered. Third, methods addressing right-skewed and right-censored data were used.
The present study has some limitations in coverage of all potential treatments and resource use. Treatments and resources used for side-effects from chemotherapy or radiation treatment were not collected, and neither were data on family practitioner visits, proton pump inhibitor medications or costs relating to end-of-life healthcare where they were incurred outside hospital.
These additional costs are likely to be orders of magnitude lower than those for surgery, Nevertheless, the present assessment of specific costs of surgical versus non-surgical treatment is still likely to be valid and representative of these treatment pathways. In addition, resource use has been presented separately before applying unit prices, allowing costs to be estimated in other jurisdictions that apply their own pricing schedules. The evidence of relative treatment cost from Australia should translate well to the UK and mainland Europe, given similar publicly funded universal healthcare systems, populations and relative prices (for example, the cost of endoscopy will be significantly higher than that of chest X-ray in both settings), and the use of purchasing power parities in exchange rate conversion. Ultimately, the data and analysis presented will be most useful in economic modelling studies of new technologies for managing oesophageal cancer where detailed cost and resource estimates are required.
Supporting information
Additional supporting information may be found in the online version of this article: 10.1 *Cancer stage was imputed using regression methods for half the sample where data were missing. †Endoscopy was a condition of entry into the study. ‡Includes additional positron emission tomography (PET) or computed tomography (CT) in the diagnostic phase. §Values denote the number of administrations for the four most commonly employed agents; some patients received more than one agent. ¶Values denote number of weeks of radiotherapy. #Median number of inpatient days. was imputed using regression methods for half the sample where data were missing. †Endoscopy was a condition of entry into the study. ‡Includes additional positron emission tomography (PET) or computed tomography (CT) in the diagnostic phase. §Values denote the number of administrations for the four most commonly employed agents; some patients received more than one agent. ¶Values denote number of weeks of radiotherapy. #Some patients had more than one stent placement. 
